Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Key Points

• Lexicon will report its Q1 2026 results before the market opens on Thursday, May 7 at 8:30 AM ET; analysts expect EPS of ($0.04) and revenue of $9.79 million.
• Insiders have been buying recently—Invus Global purchased 1,538,462 shares at about $1.30 and director Raymond Debbane bought 100,000 shares at $1.47—with insiders now owning roughly 14% of the stock.
• Analyst sentiment is mixed (two Buys, one Sell) with notable targets from Citi and HC Wainwright and an average price target of $4.15.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $9.79 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 41.94% and a negative net margin of 101.08%.The firm had revenue of $5.49 million for the quarter, compared to analyst estimates of $3.14 million. On average, analysts expect Lexicon Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexicon Pharmaceuticals Stock Up 1.2%

Lexicon Pharmaceuticals stock opened at $1.63 on Friday. Lexicon Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $1.95. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.88 and a quick ratio of 4.87. The stock has a market cap of $690.60 million, a PE ratio of -11.64 and a beta of 0.97. The stock's fifty day moving average is $1.65 and its two-hundred day moving average is $1.45.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Citigroup increased their price objective on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the company a "buy" rating in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Lexicon Pharmaceuticals in a research note on Monday, March 23rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Lexicon Pharmaceuticals has an average rating of "Hold" and an average target price of $4.15.

Insider Buying and Selling at Lexicon Pharmaceuticals

In other news, Director Invus Global Management, Llc bought 1,538,462 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, February 2nd. The stock was acquired at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the acquisition, the director owned 1,538,462 shares of the company's stock, valued at approximately $2,000,000.60. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Raymond Debbane bought 100,000 shares of the firm's stock in a transaction that occurred on Monday, February 23rd. The stock was purchased at an average cost of $1.47 per share, with a total value of $147,000.00. Following the completion of the transaction, the director owned 1,904,186 shares in the company, valued at approximately $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 1,790,462 shares of company stock valued at $2,369,981 in the last 90 days. 14.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several large investors have recently modified their holdings of LXRX. Virtu Financial LLC purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $42,000. Invesco Ltd. raised its position in Lexicon Pharmaceuticals by 14.1% in the 4th quarter. Invesco Ltd. now owns 594,883 shares of the biopharmaceutical company's stock valued at $684,000 after purchasing an additional 73,480 shares during the last quarter. Millennium Management LLC boosted its stake in Lexicon Pharmaceuticals by 25.9% during the 4th quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company's stock worth $5,545,000 after purchasing an additional 991,073 shares during the period. ExodusPoint Capital Management LP acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter worth $309,000. Finally, Graham Capital Management L.P. purchased a new position in Lexicon Pharmaceuticals during the 4th quarter worth $126,000. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.